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Introduction
is the main virulence factor of the parasite and contributes to the pathophysiology of severe malaria. The 48 sequestration of infected erythrocytes in the capillaries leads to hypoxia, occlusion and endothelial 49 activation. In CM pathophysiology, the sequestration of iE in the brain capillaries is believed to trigger coma 50 and brain swelling (2) . 51
Among the proteins exported at the erythrocyte's surface, three variant surface antigens (VSA) families have 52 been described: the repetitive interspersed family (RIFIN) (3, 4) , subtelomeric variable open reading frame 53 (STEVOR) (5, 6) and Plasmodium falciparum Erythrocyte Membrane Protein 1 (PfEMP1) (7) , which is the 54 most described VSA family. They are encoded by the multigenic var gene family (8) (9) (10) , consisting in ~ 60 55 copies per parasite genome. The diversity among var sequences is almost endless (11, 12) thus participating 56 to the infected erythrocyte ability to evade the immune system. 57
PfEMP1 proteins are high molecular weight transmembrane proteins , and are composed of 58 an intra-erythrocytic segment, which is conserved, and a highly variable extracellular segment (13) . The 59 extra-erythrocytic segment is composed of 4 to 9 alternated Duffy Binding Like (DBL) or Cystein Inter 60 Domain Rich (CIDR) domains. The nature and the arrangement of these domains determine the binding 61 phenotype of the infected erythrocyte (13, 14) . 62
Among the PfEMP1 receptor in human endothelium, the most common is the broadly expressed in human 63 cells CD36, but it is not related to any specific form of malaria. In the context of severe malaria, two human 64 host receptors for PfEMP1 binding have been identified: the InterCellular Adhesion Molecule-1 receptor 65 (ICAM-1) (15) and the Endothelial Protein C Receptor (EPCR) (16) , both expressed by brain endothelial 66 cells (17) , and co-localized with the sequestered iEs (15) . Specific domains from PfEMP1 are known to 67 interact with ICAM-1, including the Domain Cassette 4 (DC4) (DBLα1.4/1.1-CIDRα1.6-DBLβ3) (18) . The 68 binding domain is located in the C-terminal third of the DBLβ3 (18) . A study conducted on lab-adapted 69 patient's isolates after selecting on ICAM-1 highlighted that the residues involved in PfEMP1 binding to 70 ICAM-1 are highly variable with a limited binding pattern (19) (20) . 71 EPCR role in PfEMP1 binding has been more recently discovered (16) . EPCR binding is mediated by highly 72 variable but structurally conserved CIDRα1 PfEMP1 domains (more precisely CIDRα1.1 and CIDRα1.4-73 1.8) (21, 22) . Importantly, the level of PfEMP1transcript associated with EPCR binding is higher in samples 74 from patients suffering from severe malaria, and increases with the disease severity (21) . 75
A dual-binding with EPCR and ICAM-1 has been suggested, since not all CM isolates present an increase in 76 binding-EPCR PfEMP1 coding transcript (23) . In addition, expression levels of var coding transcripts are 77 increased in parasites able to bind to EPCR, ICAM-1 and CD36 in vitro enforcing the idea of a mutual 78 binding (24) . The expression of DBL involved in ICAM-1 binding is associated with dual ICAM-1 and 79 EPCR binding (20) . 80
Despite their high diversity, PfEMP1 proteins are a target of naturally acquired immunity against P. 81 falciparum (25) , and the parasite express VSA corresponding to gap in the antibodies repertoire from an 82 individual (26, 27) . Therefore, identification and characterization of severe malaria associated PfEMP1 83 proteins is crucial. It is believed that despite the endless variability of PfEMP1 proteins (28) , a cross-84 reactivity between expressed epitopes exists (29) , as children in endemic area acquire protective immunity 85 to the high binding phenotypes after a limited number of infection compared to PfEMP1 variability (26) . 86
PfEMP1 proteins are a proposed target for vaccine to protect people against severe forms of malaria (25, 87 30) . 88
Most field studies looking for P. falciparum binding phenotypes are based on molecular biology analysis, 89 and have shown that transcript coding for specific PfEMP1 domains expression level are associated with 90 disease outcome (21, 24, 31, 32) . However, this strategy is currently limited to the already identified 91 PfEMP1 domains and does not give proficiency of the expressed proteins. 92
To complement this deficiency, mass-spectrometry-based proteomics is a powerful and sensitive tool for 93 bottom-up protein identification after trypsin digestion. The application of mass spectrometry for VSA 94 identification, and more especially PfEMP1 identification remains challenging for the following reasons. 95
First, PfEMP1 are transmembrane proteins, and therefore present hydrophobic segments which decrease its 96 solubility and its accessibility to proteases such as trypsin. Second, PfEMP1 are high molecular weight 97 proteins (250-350 kDa), and finally, PfEMP1 are highly variable in sequences, yet database repository is 98 usually simplified by eliminating redundancy. Thus, they do not reflect the natural sequence diversity which 99 may occur in such a context. 100 To date, PfEMP1 identification with mass-spectrometry remains limited. In fact, the identification of the 101 semi-conserved variant VAR2CSA in the context of Pregnancy Associated Malaria has been performed 102 (33) , but the identification of PfEMP1 variant in a context of severe malaria (CM or SA) has not been 103 reported yet. The association of PfEMP1 domains with clinical outcome (UM, CM and Pregnancy 104 Associated Malaria) was performed, with relaxed analysis parameters to allow the identification of PfEMP1 105 domains (34) .
106 To identify PfEMP1 associated with P. falciparum clinical outcome in endemic settings, we used a 107 "proteogenomic" strategy on field sample from children from Benin, West Africa, retrieved from May 2016 108 to August 2016. Specific PfEMP1 sequences from each isolate were reconstructed, using whole genome 109 sequencing (WGS) data to enrich the protein database ( Figure 1 ). We analyzed the whole proteome of 110 samples from patients presenting either CM, SA or UM, and attribute PfEMP1 sequences within these 111 samples. Corresponding samples were analyzed in RNAsequencing for PfEMP1 expression analysis, in 112 relation to proteomic results.
113 We managed to identify the PfEMP1 sequence associated with 4 CM samples, 9 SA and 9 UM samples 114 using mass spectrometry (MS). For two samples, the relative expression levels from the PfEMP1 identified 115 in MS was assessed using RT-qPCR using the corresponding mRNA. We confirmed the expression of 116 several PfEMP1 within a single field isolates and provided the first identification at the patient's level of 117 PfEMP1 expressed by the parasite in the context of acute P. falciparum infection. We were also able to 118 predict PfEMP1 structure within each newly identified sequence. 119 120 121 We then focused on a set of 120 proteins from PlasmoDB reference, corresponding either to PfEMP1, or to 139 other proteins associated with knobs formation (Supplementary data Table 3 ). The presence of skeleton 140 binding protein 1 (Pf3D7_0501300) and EMP1 (Pf3D7_0730900) was assessed in all samples except SA09.
141 Focusing on PfEMP1, we observed that the conserved ATS coding region was the only site for PfEMP1 142 mRNA identification using reference sequences from PlasmoDB. We then performed a selective mapping of 143 RNAsequencing reads using the sequences from var genes reconstruction, which allowed to identify the 144 expressed var transcript for 3 samples ( Supplementary Table 4 ). 145 Protein identification 146 Protein identification was performed using a home-made database (reference sequences from human and P. 147 falciparum repositories, and the assembled var from field samples) containing 295,601 protein sequences, 148 among which 87,489 were P. falciparum-associated sequences, while the other referred to the human 149 proteome. Overall, we identified 3,300 proteins. After applying contaminant depletion and identification 150 criteria, 3 214 proteins remained. A total of 1,302 were associated to the human proteome, and 1,912 to P. 151 falciparum's. Among those later, 460 proteins were identified as P. falciparum membrane-associated 152 proteins, including 60.4% of hypothetical or putative, 12 % of PfEMP1s, 3.5% of RIFINs, 0.9% of 153 STEVORs, 1.5% of PHISTs and 21.7% belong to other protein families. 154 A total of 155 proteins associated with PfEMP1 were identified, among which 96 were unique proteins, and 155 clustered in 55 protein groups. Only 10 of the identified PfEMP1 (as part of protein group, or majority 156 protein) were known sequences from public database repository (Uniprot and PlasmoDB). All other 157 identified PfEMP1 sequences resulted from the translation of the reconstructed var genes from our samples. 158 PfEMP1 identification and composition 159 We then focused on the 55 protein groups associated to PfEMP1 proteins. The minimum peptide number for 160 protein identification was 2. Sequence coverage ranged from 0.6 to 24.6 % maximum. Average molecular 161 weight of the identified PfEMP1 was 228.3 kDa. Using the VarDom online server, we reconstructed the 162 domain architecture from the identified proteins ( Figure 2 ). Fifty-three sequences displayed at least one hit 163 with the repository sequences. NTS domain was found in 73.6 % of the sequences (39/53 sequences 164 presenting at least one hit with VarDom reference sequences) and 97 % (38/39) of the sequences presenting 165 NTS displayed the following combination: NTS-DBLα-CIDRα. The three-major head-terminal domain 166 organizations were the following: NTS-DBLα-CIDRα-DBLβ (58.9%; n = 23/39), NTS-DBLα-CIDRα-167 DBLδ (30.8%; n = 12/39) and NTS-DBLα-CIDRα-DBLγ (2.6%; n = 1/39). To attribute more precisely 168 subdomains to the identified PfEMP1 proteins, we performed a local blast from the 110 peptides associated 169 to the PfEMP1 proteins against the VarDom sequences repository (Figure 3 and Figure 4 ). Fifty four percent 170 (n = 60/110) of the peptides displayed at least one hit with the reference sequences from VarDom (median 171 hit number per peptide was 5 (interquartile range [2; 23])), among which 40/110 peptides displayed hits with 172 more than 90% identity with a reference sequence (among these, median number of hits per peptide was 2 173 (interquartile range [1; 5] )). Most of the obtained hits from peptides with reference sequences corresponded 174 to ATS sequences (171 hits), and 71 hits covering DBL domains (among them, 25 for DBLα, 20 for DBLβ, 175 14 for DBLδ, 1 for DBLε and 11 for DBLγ). One hit corresponded to NTS domain. Subdomain attribution 176 was performed successfully for the corresponding peptides. No peptide was issued from CIDRα and seven 177 peptides where issued from DBLβ.
178 The specific search of the binding pattern for ICAM-1 retrieved 6 identifications within the PfEMP1 179 sequences identified in mass spectrometry. 180 PfEMP1 associated with clinical outcome of infection 181 Among the identified PfEMP1 proteins in LC-MS/MS, 11 were shared between all patient's group, 2 were 182 specifically associated with CM, 5 with UM and 18 with SA. SA and CM shared 8 proteins, UM and CM 14 183 proteins, and SA and UM 6 proteins ( Figure 5 ). The corresponding PfEMP1 are listed in Table 1 .
184 The PfEMP1 containing ICAM-1 binding pattern were associated to several protein groups, and matching 185 with 5/9 of SA samples, 3/4 CM, and 4/9 UM samples ( Figure 3 ). However, no peptide was identified 186 corresponding directly to the pattern. We performed a 3D structure prediction (using 3D7 template available 187 in PDB) from all DLBβ identified within the sequences obtained from WGS and identified in LC-MS/MS. 188 Average quality score was 0.554 (± 0.047). RMSD calculation showed that the obtained DBLβ structure are 189 highly similar (Figure 6 A) .
190 Focusing on CIDRα, we were able to produce acceptable (quality score 0.470 ± 0.092) folding for all 191 sequences except two which were excluded from the clustering. As expected, we observed that CIDRα1-192 like sequences and CIDRα "non α1" were clustered respectively (Figure 6 B ). Using PyMol visualization of 193 predicted 3D structure, we focused on the two α helix involved respectively in CD36 binding and interaction 194 with EPCR (35) . Among the CIDRα sequences, 14 presented a CIDRα "non α1" helix fold, among which 12 195 were folded correctly.
196 We then predicted the structure from CIDRα linked to DBLβ presenting ICAM-1 binding predicted pattern -197 6 PfEMP1 proteins containing DBLβ-ICAM-1 binding pattern ( Figure 6C ). These CIDRα presented a 198 phenylalanine (5/6 sequences) or tyrosine (1/6 sequences) in position 187 (1/6 sequences), 188 (3/6 199 sequences), 184 (1/6 sequences), 190 (1/6 sequences) from the corresponding CIDRα ( Figure 6B ). These 200 amino acids were juxtaposed and exposed similarly to the phenylalanine involved in EPCR binding from 201 Hb3var3 CIDRα 3D structure. 202
Genomic and transcript data for specific protein identification 203 Since we had access to preserved RNA for 2 samples in addition to RNAsequencing data (CM04 and SA06 204 at 3 additional sampling time each: H0 (diagnosis of malaria) and post diagnosis sample, H16, H24 for 205 CM04 and H0, H8, H16, for SA06), we selectively designed primers that would specifically amplify the 206 PfEMP1 transcripts from the mass spectrometry matching sequences (Figure 1 ). Our goal was to assess 207 which ones of these proteins are expressed, and their corresponding relative expression level using the Tu 208 measurement method. Using alignment tools, we managed to find discriminant primers between the 6 209 identified sequences for sample SA06 (g45, g949, g1030, g1025, g150 and g62) and the 3 sequences (g276, 210 g299 and g522) for sample CM04. Identified primers are presented in Supplementary data table 1 and 211 quantification on Figure 7 for sample SA06. The amplification profile of reference genes was not satisfying 212 for CM04-H0 and SA06-H08 samples, which were excluded from the analysis. For patient CM04, at H16, 213 transcript expression was at the detection level threshold and no major transcript was identified. For patient 214 CM04, at H24, the major transcript is g276 followed by g299 and g522 (Tu respectively: 43.26 -4.24 -215 1.32). For sequences that displayed different Melting Temperature (Tm), selective sequencing did not reveal 216 differences between sequences, except for CM04 g276 sequence amplified with the designed primers.
217 218
Discussion

219
The evolution of P. falciparum infection from uncomplicated forms of the disease to cerebral malaria, the 220 most fatal, is a complex phenomenon which entails host and parasite factors, in addition to socio-economics 221 settings (36) . There are strong evidence that the PfEMP1 proteins are involved in the disease progression 222 since they allow the parasite to bind to host endothelium (14) . It is believed that a distinct subset of PfEMP1 223 proteins is involved in severe malaria (23, 37) , most likely by providing to the parasite the ability to 224 sequester to a given receptor. However, PfEMP1 identification in natural infection remained challenging, 225 due to the large size of PfEMP1 and their high sequences diversity. Recently, Jespersen et al (23) provided a 226 new insight towards var genes sequences expression analysis in patient's sample using transcript 227 reconstruction after DBLα barcoding. They confirmed the preferential expression of CIDRα associated with 228 EPCR binding in severe malaria patients.
229 We used a mass spectrometry-based proteomic approach to analyse the P. falciparum proteome in the 230 context of severe malaria (SA and CM) compared to UM. We aimed to accurately identify, at the protein 231 level, the PfEMP1 sequence variants associated with diseases severity. To this end, we initiated a 232 "proteogenomic" study of field samples. In collaboration with the WT Sanger institute, we performed whole 233 genome sequencing of the samples and had access to the assembled var gene sequences of the samples. 234 Second, we performed RNAsequencing of these samples and analysed by LC-MS/MS the corresponding 235 matured parasites. RNAsequencing reads were aligned for P. falciparum transcripts expression both on 236 reference transcriptome and sequences issued from WGS of our samples. Reference database allowed the 237 identification of var transcripts; however, all mapped reads were in semi conserved ATS coding region.
238 Protein identification was performed by matching mass-spectrometry data against a custom database 239 containing the translated PfEMP1 sequences (Figure 1 ). As anticipated, most of the identified PfEMP1 240 (considering all PfEMP1 from all protein group) came from the newly added sequences to the database 241 (10/96 were known sequences), confirming the validity of our approach.
242 The technical improvement allowed us to identify more proteins than previously published studies (34, 38) , 243 with higher sequence coverage. We identified a set of 55 PfEMP1 associated in protein group. We 244 investigated the structure of theses sequences and found that the two main domain organisations were NTS-245 DBLα-CIDRα-DBLβ and NTS-DBLα-CIDRα-DBLδ. The high proportion of NTS-DBLα-CIDRα-DBLβ 246 among expressed PfEMP1 identified in our samples compared to genomic sequences within the same 247 sample pool reflects the preferential expression of the PfEMP1 containing this pattern compared with the 248 other PfEMP1 protein sequences in the studied context. The CIDRα-DBLβ tandem is associated with the 249 potential "double binding" PfEMP1 (20, 24) , targeting both ICAM-1 (through DBLβ (20) ) and EPCR 250 (through CIDRα (22) ) human endothelial receptor. PfEMP1 binding pattern to ICAM-1 was not identified 251 with specific peptides; however, proteins containing the binding pattern were identified in our samples (all 252 malaria clinical presentation). We were able to predict domains structure for the CIDRα from PfEMP1 253 identified within our sequences pool. The proportion of "non α1" CIDR sequences identified is lower than 254 the corresponding sequences in parasite genomes, ( CIDRα2-6 represent 85% of PfEMP1 in parasite 255 genomes) (37), enforcing the idea of preferential expression from PfEMP1 encoding EPCR binding CIDRα 256 within malaria clinical presentation. In addition, all sequences presenting CIDRα-DBLβ-[ICAM-1 binder] 257 harboured EPCR binding like CIDRα, enforced by 3D representation of domain structure.
258 For two isolates (SA09 and CM04), the identified PfEMP1 proteins were directly and unambiguously 259 associated to transcript from the same isolate. To ensure whether several PfEMP1 proteins were expressed in 260 the sample or if this was due to the identification method (peptides mapping sequences), we performed 261 selective sequencing of the corresponding mRNA within the same sample. We managed to identify the most 262 expressed transcript for one (CM04-H24), and the two main expressed transcripts for the other (SA09-H16). 263 However, transcript corresponding to the other identified proteins existed at low expression level. It seems 264 legitimate that along multiplication cycles, parasites express different PfEMP1. Furthermore, natural 265 infection are often polyclonal and patients in endemic areas harbour usually 2 to 3 clones (39) . However, we 266 identified more sequences per sample than clones, strengthening the idea of simultaneous expression of 267 several sets of PfEMP1 proteins by the parasite population within an individual. In addition, there are less 268 PfEMP1 proteins identified in mass spectrometry compared to RNA sequencing/RT-qPCR approach. It 269 seems plausible that, for technical reasons, PfEMP1 identification in LC-MS/MS provides a subset of the 270 major proteins associated with each sample. In addition, all mRNA might not occur translation, as 271 pseudogenes from var family are described. mRNA analysis reflects both coding and non-coding RNA 272 expressed by a sample. 273
Focusing on patient's group (CM, SA and UM), no consensus or highly similar sequence was obtained for a 274 given clinical outcome of P. falciparum infection. Most sequences were shared between patient groups, 275 since their identification relies mostly on reads mapping in the semi-conserved region ATS. We could not 276 specifically identify sequences coding for the ICAM-1 binding pattern or the CIDRα involved in EPCR 277 binding within severe malaria group. However, for sample SA06, one of the major proteins and transcript 278 identified corresponds to a sequence expressing the binding pattern for ICAM-1.
279 We were not able to attribute domains subtype to the obtained sequences. The high diversity of PfEMP1 280 protein sequences compared with the repository database prevented us from assigning a subdomain to every 281 domain. This limitation did not allow us to specifically identify subtypes of domains, in relation to reference 282 sequences, associated with P. falciparum infection severity. However, selective alignment from obtained 283 peptides to reference sequences repository allowed to identify domain subtypes for 36% (40/110) of 284 identified peptides. This difficulty to attribute a domain may be the consequence of either: the peptide being 285 shared between two or more domains, or the peptide has never been previously identified thus absent from 286 the database (Figure 2 ). Variant protein identification in mass spectrometry is challenging, since protein 287 identification is the reflection of the quality of the database available. Restrictive use of reference sequences 288 from public repositories reduces the "chance" of protein identification, but we ride out this challenge with 289 our home-custom sequence database obtained through whole genome sequencing of our samples. The 290 variability of PfEMP1 primary sequence was overcome using protein structure modelling, which allowed us 291 to classify the CIDRα identified within predicted binding target. We confirmed that PfEMP1 protein 292 sequences which display ICAM-1 binding pattern present CIDRα domains with EPCR binding folding. 293 This study highlights the perspective offered by proteogenomic approaches for VSA studies. Using a home-294 made database containing PfEMP1 sequences obtained from WGS of the corresponding samples, we 295 managed to identify specific PfEMP1 pattern associated with each sample, where RNAsequencing alone 296 could not discriminate the expressed PfEMP1 within a sample. However, the sequence coverage of the 297 identified proteins remained limited. Further attempts should focus on increasing the number of identified 298 peptides per protein, using for example selective enrichment in membrane proteins. The identification of 299 new PfEMP1 variants using whole genome sequencing and the confirmation of their expression at the 300 protein level is, to our knowledge, the first report using field isolates. 301
In conclusion, we identified PfEMP1 proteins expressed by parasite in patients presenting several forms of 302 malaria. This is the first report of PfEMP1 direct identification and is providing insight towards malaria 303 pathogenesis understanding. PfEMP1 are adhesin which mediates iE adhesion to the host endothelium. The 304 high proportion of CIDRα among the identified sequences enforce the idea that iE sequestration occurs 305 either through CD36 binding, or EPCR binding, pending of clinical presentation (22, 40) . We also 306 preferentially identified PfEMP1 protein harbouring DBLβ, among which 20% (6/30 identified DBLβ) 307 displayed the binding pattern for ICAM-1. This strengthen the hypothesis that DBLβ is involved in the 308 disease development, as demonstrated with antibodies against DBLβ in Tanzania (41) and Papua New 309 Guinea (42) . Antibodies against full length DBLβ3 PF11_0521 are associated with reduction risk of severe 310 malaria and protection against clinical infection (42) . We demonstrated that predicted 3D structure from all 311 DBLβ identified in the studied followed closely DBLβ3 PF11_0521 structure, enforcing the idea of 312 DBLβ3 PF11_0521 as a vaccination target to prevent severe malaria. Further studies to identify immune 313 response to DBLβ3 PF11_0521, in combination with different CIDRα subtype are needed. There is little doubt 314 that upcoming strategies to prevent severe malaria will target DBLβ3 PF11_0521 in combination with EPCR 315 binder CIDRα in a multi epitope vaccination strategy. 316 Our study opens opportunities to identify PfEMP1 variants and later implement these newly identified 317 sequences in PfEMP1 based vaccine development strategies. However, our approach was restricted to one 318 geographic area (Benin, West Africa) and included a limited number of patients. Further studies should 319 include patients from various P. falciparum endemic areas to better represent PfEMP1 associated within P. 320 falciparum disease in general and specifically to severe malaria. 321 322
Material Transcriptome studies 345 Ring staged parasite were preserved in 5 volumes of pre-warmed (37°C) TriZol (Life Technology), vortexed 346 then immediately frozen at -80°C until further utilization. RNA was extracted as described (43) , then 347 digested with DNAse I (Qiagen) and purified using RNEasy MinElute Cleanup kit column (Qiagen). 348 Absence of genomic DNA was assessed by the absence of amplification of p90 gene in qPCR from the 349 direct use of the RNA extract, using Syber Green reagent (Life Technology) on Rotorgene 6000 (Corbett 350 Technology). RNA quality was assessed using PicoChip Agilent 2100TM Bioanalyzeur profile (Agilent). 351 Only RNA presenting a RNA Integrity Number (RIN) > 7 were retained for downstream analysis (44) . RNA-Seq preprocessing includes trimming library adapters and performing quality controls. The raw data 359 (fastq) were trimmed with Trimmomatic (45) tool for Phred Quality Score Qscore >20, read length >30 360 bases, and ribosome sequences were removed with tool sortMeRNA (46) . Reads were mapped against the 361 Plasmodium falciparum 3D7 reference genome (PlasmoDB v35) and against the reconstructed sequences 362 from WGS, using STAR (version 2.5.4b) with default parameters. A sequence was considered as 363 successfully sequenced if more than 70% of the transcript was covered with at least 5 reads. 364 Obtention of mature forms from P. falciparum 365 Blood samples were matured in vitro for 18 to 32 hours in RPMI medium supplemented with human serum 366 and Albumax (Gibco) and preserved after MACS TM (Myltenyi Biotech) enrichment as described (33) . 367 Protein extraction and sample preparation for mass spectrometry analysis 368 Whole cell infected erythrocyte lysates were solubilized and digested in solution using trypsin (Promega, 369 sequencing Grade). Briefly, 50 μg of proteins from whole cell lysates were diluted to 25 μl in solubilization 370 buffer (1% sodium desoxycholate, 100 mM Tris/HCl, pH8.5, 10mM TCEP, 40 mM chloroacetamide), 371 heated for 5 min at 95°C and sonicated three times for 30 s. Once at room temperature, extracts were diluted 372 with 25 μl Tris-ACN buffer (50mM Tris/HCl pH 8.5, 10%ACN). Collected peptides were fractionated in 5 373 fractions per sample by strong cationic exchange (SCX) StageTips (47) . 374
Mass spectrometry analysis 375 Mass Spectrometry (MS) analysis were performed on a Dionex U3000 RSLC nano-LC-system coupled to an 376 Orbitrap-fusion mass spectrometer (Thermo Fisher Scientific) as described (48) . Peptides were separated on 377 a C18 reverse-phase resin (75-μm inner diameter and 15-cm length) with a 3-hr gradient. The mass 378 spectrometer acquired data throughout the elution process and operated in a data-dependent scheme. 379 Accession number 380 The raw reads were available under the accession number listed in supplemental data 5. VarDOM server for 381 var genes is available at the following address www.cbs.dtu.dk/services/VarDom/. PlasmoDB reference 382 sequences are available on EupathDB portal dedicated to Plasmodium (http://plasmodb.org/plasmo/). 383 Database construction 384 To get an accurate identification of proteins, a database was created as follows: Since our samples have been 385 sequenced by the MalariaGen consortium (UK), whole genome sequences were available. Reconstructed var 386 genes were kindly provided by Thomas Otto, Matt Berriman and Chris Newbold from the Welcome Trust 387 Sanger Institute. We concatenated P. falciparum proteins sequences from PlasmoDB (v35) Uniprot and 388 NCBI. We added our own PfEMP1 sequences, obtained after in silico translation from var genes 389 reconstruction. Duplicate sequences were removed. FASTA sequence headers were uniformed to facilitate 390 MaxQuant sequences analysis. 391 Raw data processing 392 The mass spectrometry data were analyzed using Maxquant version 1.5.2.8 (49) . The database used was our 393 homemade database (see above section) and the list of contaminant sequences from Maxquant. The 394 precursor mass tolerance was set to 4.5 ppm and the fragment mass tolerance to 0.5 Da. 395 Carbamidomethylation of cysteins was set as constant modification and acetylation of protein N-terminus 396 and oxidation of methionine were set as variable modifications. Second peptide search was allowed, and 397 minimal length of peptides was set at 7 amino acids. False discovery rate (FDR) was kept below 1% on both 398 peptides and proteins. Label-free protein quantification (LFQ) was done using both unique and razor 399 peptides. At least 2 such peptides were required for LFQ. The "match between runs" (MBR) option was 400 allowed with a match time window of 1 min and an alignment time window of 30 min. 401
For analysis, LFQ results from MaxQuant were imported into the Perseus software (version 1.5.1.6) . 402 Reverse and contaminant proteins were excluded. Only proteins from P. falciparum were selected for further 403 analysis. We then focused on the membrane associated and putative proteins from P. falciparum. 404 Protein sequence analysis and structure prediction 405 PfEMP1 sequences were aligned using the VarDom server (available at 406 http://www.cbs.dtu.dk/services/VarDom/) for domain type identification (11) . We specifically searched the 407 pattern for ICAM-1 binding I[V/L]x 9 N[E]GG[P/A]xYx 27 GPPx 3 H (20) in the identified PfEMP1 sequences 408 using the ProSite online interface (50) . 409 Using domain limitation performed with VarDOM server, we predicted the structure of the CIDRα and 410 DBLβ domains identified within our sequences. Structure were generated using Modeller (v9.20.) (51) . We 411 selected templates from the Protein Data Bank (52) using BLAST algorithm. Template selection was 412 performed manually using BLAST results, sequence coverage within each template and template quality. 413 DBLβ structure prediction was performed using PDB 5mza (PF11_0521). For the CIDRα domain, the 414 following templates were used: 4v3d (from HB3var03), 4v3e (from IT4var07), 3c64 (MC179) and 5lgd 415 (from MCvar1). Template and query quality scores were calculated using ProQ3 online tool. For 5mza the 416 quality score was 0.560. For 4v3d, 4v3e, 3c64 and 5lgd, quality scores were respectively 0.484, 0.585, 0.396 417 and 0.540. For each domain, 5 models have been generated, and 4 additional models were generated after 418 loop refining. Template and query mapping has been performed using align2D tool from Modeller script. 419 For structure modelling using several templates, we used salign script (part of Modeller script). 420 The choice of the best model was made based on the Discrete Optimized Protein Energy (DOPE) score 421 values. In order to analyze and compare the modeled structures were compared using the Bio3D v 3.2 R 422 package (53) . Structure comparison was based on Root-Mean-Square Deviation (RMSD) calculated using 423 Cα distance from predicted structures. Obtained RMSD values were clustered using Bio3D R package (53) . 424 Statistical analysis 425 Patient's samples information's were compared between the 3 patient's groups (UM, CM and SA) using 426 one-way ANOVA. Bonferroni's Multiple Comparison Test was applied for individual group comparison. 427
We considered a p value < 0.05 as significant. Qualitative data were compared with Chi Squared test using 428 contingency table. All analyses were performed using Prism v5 (Graphpad). 429 Primer design 430 We tried to specifically assign PfEMP1 expression within the samples. In addition to RNAsequencing data, 431 we disposed of preserved RNA from 2 samples. Our strategy was as follows: first, we compared the 432 sequences of the identified proteins using Multalin (54) . Second, we designed specific primers targeting the 433 sequences using Primer3Plus web interface (55) . Finally, we assessed primers specificity using BLAST 434 tools. (Primers are listed in Supplementary data 2). 435 RT-qPCR and PCR 436 RNA was preserved using Trizol reagents (Life Technology) and RNA extraction was performed as 437 described (43) . cDNA was obtained using Superscript II (Life Technology) retrotranscriptase following the 438 manufacturer's instructions. 439 qPCR was performed using Power SYBR Green PCR Master Mix (Applied Biosystems) on Rotorgen 440 (Corbett technology) as described (34) . Melting stage was set up as default on the Rotorgen software. PCR 441 specificity was assessed by the melting temperature (Tm). We considered that a sequence is unique for Tm 442 included in the range Tm +/-0.5°C. Transcript expression was quantified using the Transcript Unit (Tu) 443 method, as described by Lavsten et al (31) . GAPDH and Seryl-tRNA synthetase transcripts were used as 444 reference genes. 445 For transcripts which displayed a Tm difference upper than 0.5°C for a same primer set, we performed a 446 conventional PCR using AmpliTaGold DNA polymerase (Applied Biosystem) with the following 447 conditions: initial denaturation at 95°C for 10 min, followed by 52°C hybridization for 30s -68°C 448 elongation for 15 s, repeated 35 times. PCR products length was assessed using 2% agarose gel containing 449 Syber Safe (Life Technology) at 1/10,000. 450 Amplicons were purified using the QIAquick PCR Purification Kit (Qiagen). The purified fragments were 451 sequenced with BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems) using g949, g150 (for 452 patient SA06), and g299 primers (for patient CM04) (Supplementary data 1) . The sequence reaction 453 products were purified using the BigDye XTerminator® Purification Kit (Applied Biosystems), in 454 accordance with the manufacturer's instructions. The purified products were sequenced using an ABI Prism 455 3100 analyzer (Applied Biosystems), and the sequences were analyzed using DNA Baser v4 (Heracle 456 BioSoft). 457 458
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